Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,422,792

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

by Zacks Equity Research

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

Ritujay Ghosh headshot

5 Defensive Stocks to Buy Amid Lingering Market Volatility

by Ritujay Ghosh

Volatility has gripped Wall Street again. So, investing in defensive stocks like McKesson Corporation (MCK), Entergy Corporation (ETR), PepsiCo, Inc. (PEP), Johnson & Johnson (JNJ) and Atmos Energy Corporation (ATO) is a safe bet.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for HDV

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRW

Zoetis' (ZTS) Companion Animal Products to Boost Revenues

by Zacks Equity Research

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.

Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?

by Zacks Equity Research

With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.

Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher

by Zacks Equity Research

Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.

J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange

by Zacks Equity Research

J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

by Zacks Equity Research

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Nalak Das headshot

5 Blue-Chip Stocks for a Stable Portfolio Amid Volatility

by Nalak Das

We have narrowed our search to five blue-chip such stocks with strong growth potential for the rest of 2023. These are: WMT, JPM, JNJ, CAT, MCD.

Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca

by Zacks Equity Research

Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article

Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals

by Zacks Equity Research

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

by Zacks Equity Research

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Ethan Feller headshot

Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays!

Kinjel Shah headshot

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

by Kinjel Shah

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug

by Kinjel Shah

FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.

Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now

by Zacks Equity Research

J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.

AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug

by Zacks Equity Research

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

by Zacks Equity Research

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

by Zacks Equity Research

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod

by Zacks Equity Research

The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.